Nov 20, 2009 By:Patricia Van Arnum
Following its $68-billion acquisition of Wyeth, Pfizer has unveiled detailed plans for its global R&D network, which includes consolidation of its R&D facilities.
 |
Nov 19, 2009 By:Patricia Van Arnum
Following the its $68-billion acquisition of Wyeth (Madison, NJ), Pfizer (New York) Pfizer detailed plans for its global research and development (R&D) network, which includes consolidation of its R&D facilities.
 |
Nov 12, 2009 By:Patricia Van Arnum
Novartis reported that German regulatory authorities approved its adjuvanted cell culture-based Influenza A (H1N1) 2009 monovalent vaccine, Celtura. The company also said it will acquire a stake in Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical.
 |
Nov 12, 2009 By:Patricia Van Arnum
The European Medicines Agency, the European Center for Disease Prevention and Control, and the Heads of Medicines Agencies issued a European strategy for H1N1 vaccine benefit–risk monitoring.
 |
Exhibitors announce capacity expansions, service enhancements, and new products at CPhI Worldwide, the large pharmaceutical ingredients and contract services trade show, held in Madrid last month. Nov 10, 2009 By:Patricia Van Arnum
Exhibitors announce capacity expansions, service enhancements, and new products at CPhI Worldwide in Madrid.
 |
Vetter moves ahead with a new development facility in the US and expanded capabilities in Germany. Nov 10, 2009 By:Patricia Van Arnum
Vetter moves ahead with a new development facility in the US and expanded capabilities in Germany.
 |
Leading experts from an upcoming conference on biosimilars by the Drug, Chemical, and Associated Technologies Association share their insights on the manufacturing and regulatory considerations for biosimilars. Nov 10, 2009 By:Patricia Van Arnum
Leading experts from an upcoming conference on biosimilars by the Drug, Chemical, and Associated Technologies Association share their insights on the manufacturing and regulatory considerations for biosimilars.
 |
Nov 6, 2009 By:Patricia Van Arnum
The FDA has responded to a citizen petition from the Society of Chemical Manufacturers and Affiliates (SOCMA) that highlighted the disparity in inspections of domestic and foreign drug-manufacturing facilities.
 |
Nov 6, 2009 By:Patricia Van Arnum
Lonza (Switzerland) has announced a series of cost-cutting measures for the next 12¬18 months.
 |
|